shafei osteoporosis
TRANSCRIPT
![Page 1: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/1.jpg)
![Page 2: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/2.jpg)
Osteo = bone
Porosis = full of holes
Osteoporosis = means bones that are full of holes
![Page 3: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/3.jpg)
OsteoporosisOsteoporosis
• The most common metabolic bone disorder The most common metabolic bone disorder • Systemic skeletal disease characterized by:Systemic skeletal disease characterized by:
– Low bone massLow bone mass– Microarchitectural deterioration of bone tissueMicroarchitectural deterioration of bone tissue– Increased bone fragility and susceptibility to fractureIncreased bone fragility and susceptibility to fracture
Not a natural part of aging Increased risk for women, post-menopausal, over age 65 All races, sexes, and ages are susceptible Preventable and treatable!
![Page 4: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/4.jpg)
![Page 5: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/5.jpg)
In the USA, the estimated prevalence of osteopenia is 15 million in women and 3 million in men.
The estimated prevalence of osteoporosis is 8 million in women and 2 million in men.
Although, osteoporosis affects >10 million individuals in the United States, only 10 to 20% are diagnosed and treated
80% are women
Osteoporosis - Prevalence
![Page 6: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/6.jpg)
![Page 7: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/7.jpg)
![Page 8: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/8.jpg)
![Page 9: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/9.jpg)
Osteoporosis in PerspectiveLifetime risk at age 50
![Page 10: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/10.jpg)
Osteoporotic Fractures:Comparison with Other Diseases
1996 new cases,all ages184 300
750 000 vertebral
250 000 other sites
250 000forearm
250 000hip
0
500
1000
1500
2000
Osteoporotic Fractures
HeartAttack
Stroke BreastCancer
Annu
al in
ciden
ce x
100
0
1 500 000
Annual incidenceall ages
513 000
annual estimatewomen 29+
228 000
annual estimatewomen 30+
American Heart Association,1996American Cancer Society,1996
Riggs BL & Melton LJ 3rd, Bone, 1995;17(5 suppl):505S-511S
![Page 11: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/11.jpg)
All fractures are Associated With Morbidity
Cooper C, Am J Med, 1997;103(2A):12S-17S
40%
Unable to walk independently
30%
Permanentdisability
20%
Death within one year
80%
One year after an
hip fracture:
Patie
nts
(%)
Unable to carry out at least one independent activity of daily living
![Page 12: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/12.jpg)
Osteoporosis Is a Serious Public Health Problem
• Affects 10 million Americans (80% women)
• 2 million fractures yearly• Direct cost $17 billion
Distribution of Fractures
![Page 13: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/13.jpg)
Primary Care Providers Are Critical for Osteoporosis Management, Screening,
Diagnosis, and Treatment
![Page 14: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/14.jpg)
Why Recognize & Treat Osteoporosis?Why Recognize & Treat Osteoporosis?
To Prevent FracturesTo Prevent Fractures • 1.5 million fractures/yr1.5 million fractures/yr• $17 billion direct costs$17 billion direct costs• 300,000 hip fractures/yr300,000 hip fractures/yr
– 20% die20% die– 25% confined to long-term care facilities25% confined to long-term care facilities– 50% long-term loss of mobility50% long-term loss of mobility
![Page 15: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/15.jpg)
![Page 16: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/16.jpg)
launched in 2010.
![Page 17: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/17.jpg)
Vision: Towards a society free from osteoporotic fractures.
Mission: Promote health awareness among Saudi society about osteoporosis and it's relative high risk factors ,build up screening programs and comprehensive health care.
![Page 18: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/18.jpg)
The plan contain 7 targets:•primary prevention of Osteoporosis.•secondary prevention of Osteoporosis.•improve the quality of health services at it's three levels provided to Osteoporosis patients.•support monitoring, follow up, evaluation methods related to Osteoporosis control program.• implement and support research methods and respective studies related to Osteoporosis.•society partnership to control osteoporosis
![Page 19: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/19.jpg)
Types of osteoporosisPrimary Osteoporosis•Postmenopausal Osteoporosis
•Senile OsteoporosisSecondary Osteoporosis• Diet
• Drug
• Endocrine disease
• Other Systemic Disorders.
![Page 20: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/20.jpg)
Impact of OsteoporosisImpact of OsteoporosisSigns Kyphosis Loss of height Abdo bulges Clinically
diagnosed fracture
Symptoms Neck becomes
weak Pain in back Breathing
difficulties Indigestion & GOR Stress incontinence Difficulty with
mobility following a fracture
![Page 21: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/21.jpg)
![Page 22: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/22.jpg)
![Page 23: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/23.jpg)
Risk Factors• Chronic liver disease • Excessive secretion of cortisol (Cushing's syndrome)• Radiographic evidence of osteopenia or vertebral
deformity • Previous fracture not caused by a major accident • Cancer • Significant loss of height or an abnormal bend in the
upper spine (thoracic kyphosis)
Risk factors that have the potential to be modified include:
• Cigarette smoking • Excessive alcohol intake • Inactivity • Low body weight • Poor general health • Prolonged immobilization
Risk factors that cannot be modified include:
• Caucasian race • Advanced age • Female sex • Premature menopause (<45
years) • Prolonged time (>1 year) without a menstrual period
Conditions associated with osteoporosis:
• Anorexia nervosa • Malabsorption syndromes • Excessive secretion of
parathyroid hormone • Excessive secretion of thyroid
hormone • Post-transplantation • Chronic renal disease
![Page 24: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/24.jpg)
BMI less than or equal to 20
![Page 25: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/25.jpg)
BMI less than or equal to 20
![Page 26: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/26.jpg)
![Page 27: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/27.jpg)
![Page 28: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/28.jpg)
Vertebrae
Hip
Wrist
50 60 70 80
40
30
20
10
Age (Years)
Annu
al in
cide
nce
per
1000
wom
en
Incidence of Osteoporotic Fractures in Women
Wasnich RD, Osteoporos Int 1997;7 Suppl 3:68-72
![Page 29: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/29.jpg)
Hip
frac
ture
risk
(% p
er 1
0 Ye
ars)
-3
60
70
80
AGE
0
5
10
15
20
50
BMD T-score-2.5 -2 -1.5 -1 -0.5 0 0.5 1
10-Year Fracture Risk: Age and BMD
For a given BMD
,risk increases with age
Kanis JA et al, Osteoporos Int, 2001;12:989-995
![Page 30: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/30.jpg)
10-Y
ear P
roba
bilit
y of
Sy
mpt
omat
ic F
ract
ure
(%)
Age Is a Major Risk Factorfor Fracture
With kind permission from Springer Science+Business Media: Kanis JA ,et al. Ten year probabilities of osteoporoticfractures according to BMD and diagnostic thresholds. Osteoporos Int.2001;12:989-995. Adapted from Fig. 3. © 2001 International Osteoporosis Foundation and National Osteoporosis Foundation.
8070
60
50
AGE
Age 70T-score -2.524% Fx Risk
-3 -2 -1
![Page 31: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/31.jpg)
Combined Effect of Bone Density Combined Effect of Bone Density and Risk Factorsand Risk Factors
Rate ofHip Fracture/
1000Woman-Years
Bone Density
Cummings SR et al. N Engl J Med. 1995;332:767-773.
Number ofRisk Factors
27.3
14.79.4
0
5
10
15
20
25
30
Lowest Third Middle Third Highest Third
53-4
0-2
![Page 32: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/32.jpg)
![Page 33: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/33.jpg)
![Page 34: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/34.jpg)
![Page 35: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/35.jpg)
Web Version 3.4
http://www.shef.ac.uk/FRAX/. Accessed August 2014.
![Page 36: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/36.jpg)
![Page 37: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/37.jpg)
Example of Applying the FRAX Tool
Which Woman is at Higher Fracture Risk?
54 year old smoker with a T-score of -2.0or
81 year old with no prior fracture with a T-score of -1.4
10 year risk of hip fracture = 2.5%; major osteoporotic fracture = 10%
10 year risk of hip fracture = 3.2%; major osteoporotic fracture = 26%
![Page 38: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/38.jpg)
a 10 year probability of fracture in women with relation to age and T-score
![Page 39: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/39.jpg)
![Page 40: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/40.jpg)
Composition of bone…
![Page 41: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/41.jpg)
Determinants Of Peak Bone Mass
Peak Bone Mass
Physical activity Gonadal status
Nutritional statusGenetic factors
![Page 42: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/42.jpg)
![Page 43: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/43.jpg)
Bon
e M
ass
Age (years)
Attainment of Peak Bone Mass
Consolidation Age-related Bone Loss
Men
Women
Menopause
0 10 20 30 40 50 60
FractureThreshold
Compston JE. Clin Endocrinol 1990; 33:653–682.
Age Related Changes in Bone Age Related Changes in Bone MassMass
![Page 44: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/44.jpg)
![Page 45: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/45.jpg)
![Page 46: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/46.jpg)
![Page 47: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/47.jpg)
Pathogenesis• Diminished bone mass can result from:
– failure to reach an optimal peak bone mass in early adulthood
– increased bone resorption– decreased bone formation after peak bone mass has
been achieved• All three of these factors probably play a role in
most elderly persons. Low bone mass, rapid bone loss, and increased fracture risk correlate with high rates of bone turnover (ie, resorption and formation).
• In osteoporosis, the rate of formation is inadequate to offset the rate of resorption and maintain the structural integrity of the skeleton
![Page 48: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/48.jpg)
![Page 49: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/49.jpg)
![Page 50: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/50.jpg)
![Page 51: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/51.jpg)
Osteoporosis – ScreeningX-ray findings are generally insufficient for the
screening of primary osteoporosis:• A normal x-ray of bone cannot reliably measure bone density but is useful to identify spinal factures, explains back pain, height loss or kyphosis.• X-rays may detect osteopenia only when bone loss is > 30%.• X-ray findings can also suggest other causes of metabolic bone disease, such as the lytic lesions in multiple myeloma and the pseudofractures characteristic of osteomalacia.
Bone densitometry is the only method for diagnosing or confirming osteoporosis in the absence of a fracture
![Page 52: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/52.jpg)
Screening- Ultrasound DensitometryUltrasound densitometry can assess the density and structure of the skeleton and appears to predict fracture risk in the elderly. The apparatus is relatively inexpensive, portable, and uses no radiation but can be used only in peripheral sites (eg, the heel), where bone is relatively superficial. Ultrasound devices do not expose the patient to ionizing radiation.
![Page 53: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/53.jpg)
Dual-Energy X-RayAbsorptiometry
• “Gold Standard” test to determine a diagnosis
• Measures hip & spine • Painless, safe and requires no
injections• Takes 5-10 minutes• Determines risk for fracture
![Page 54: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/54.jpg)
![Page 55: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/55.jpg)
Screening - DEXADual energy x-ray absorptiometry (DEXA) • DEXA measures areal density (ie, g/cm2)
rather than true volumetric density.
• The test is non-invasive and involves no special preparation.
• Radiation exposure is minimal, and the procedure is rapid. This is the most popular and accurate test to date and the test only takes about 20 to 40 minutes, with a 5 mrem dose of radiation (a full dental x-ray is 300 mrem).
![Page 56: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/56.jpg)
![Page 57: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/57.jpg)
![Page 58: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/58.jpg)
#1 :Questions about Osteoporosis
When should Bone Density Measurement be performed?
![Page 59: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/59.jpg)
USPSTF 2010 Recommendations :Screening for Osteoporosis
BMD testing for women 65 & older BMD in 60-64 yo if ↑ fx risk
- Use WHO FRAX® risk tool
If clinical based fracture risk of 9.3% then order bone density measurement
Nelson et al Ann Int Med July 2010
![Page 60: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/60.jpg)
Who Should Have a Bone Density Test?AAFP and NOF
AAFP: Sweet MG, et al. Am Fam Physician. 2009;79(3):193-200.NOF: National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. www.nof.org. Accessed August 2014.
Women age 65 and older Men age 70 and older
Postmenopausal women and men ages 50–69 with clinical risk factors
Adults who have a fracture after age 50
Adults with a condition (e.g., rheumatoid arthritis) or taking a medication (e.g., glucocorticoids) associated with low bone mass or bone loss
![Page 61: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/61.jpg)
T-score
Normal -1 Osteopenia < -1 and > -2.5
Osteoporosis -2.5 Severe Osteoporosis
-2.5 with Fracture
OsteoporosisWorld Health Organization Criteria
Postmenopausal Caucasian with DXA measure
WHO Study Group JBMR 1994
![Page 62: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/62.jpg)
Screening - DEXA
DEXA of the proximal femur in a young woman, age 37, with unsuspected femoral-neck osteopenia (T score, -1.6).
DEXA of the lumbar spine in a young woman, age 37, with unsuspected lumbar spine osteopenia (T = -1.8)
![Page 63: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/63.jpg)
Screening - DEXA
![Page 64: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/64.jpg)
![Page 65: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/65.jpg)
T scores vs. Z scoresT score – number of SDs a patient’s
BMD deviates from a reference population of normal young adults
Z score – number of SDs a patient’s BMD deviates from a reference population of
subjects of the same age and sex Z scores indicate whether the BMD
result is expected for the patient’s age. If it is much less than expected, suspect
a secondary cause of osteoporosis (use –2 as a cutoff)
![Page 66: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/66.jpg)
![Page 67: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/67.jpg)
![Page 68: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/68.jpg)
![Page 69: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/69.jpg)
![Page 70: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/70.jpg)
![Page 71: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/71.jpg)
![Page 72: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/72.jpg)
2014 Universal Recommendations
http://www.nof.org/hcp/practice/tools. Accessed August 2014.
Counsel on the risk of fracturesEat a diet rich in fruits and vegetables (supplemented if necessary) to a total calcium intake of•1000 mg per day for men 50-70 •1200 mg per day for women ≥ 51 •1200 mg per day for men ≥ 71 Vitamin D intake should be 800-1000 IU per day (age ≥50), supplemented if necessary Regular weight-bearing and muscle-strengthening exerciseFall prevention evaluation and trainingCessation of tobacco use and avoidance of excessive alcohol intake
![Page 73: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/73.jpg)
The good news: Osteoporosis is preventable for most people!
![Page 74: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/74.jpg)
![Page 75: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/75.jpg)
75
Calcium requirements vary by age
Source: The 2004 Surgeon General’s Report on Bone Health and Osteoporosis: What It Means to You at http://www.surgeongeneral.gov/library/bonehealth
If this is your ageThen you need
this much calcium each day (mg)
0 to 6 months 2107 to 12 months 2701 to 3 years 5004 to 8 years 8009 to 18 years 1,30019 to 50 years 1,000Over 50 years 1,200
Growthspurt
![Page 76: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/76.jpg)
FOOD SERVING SIZE CALCIUM(mg)MILK - WHOLE 1 GLASS (190ML) 225
MILK - SEMI-SKIMMED 1 GLASS (190ML) 231
MILK - SKIMMED 1 GLASS (190ML) 236YOGHURT 1 POT (150g) 225
CHEDDAR CHEESE S MALL PIECE (30g) 216COTTEGE CHEESE 2 TABLESPOONS 58
ICE-CREAM 2 SCOOPS 156SARD DIINES (with bones) 2 CAN NED 230
ORANGE 1 MEDIUM 75WHITE BREAD 2 SLICES 72BAKED BEANS 3 TABLESPOONS 64
![Page 77: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/77.jpg)
77
Calcium An easy way to meet calcium needs
is consuming 3 cups (8 oz.) each day of fat-free or low-fat* milk or equivalent milk products in combination with a healthy diet. Children ages 2–8 years need 2 cups.
MyPyramid equivalents: • 8 oz. milk• 1 cup yogurt• 1-1/2 oz. natural ..or 2 oz. processed ..cheese
* Fat-free and low-fat are for health but not for calcium
differences
![Page 78: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/78.jpg)
% DV calcium: Milk group• Yogurt
1 cup (8 oz.) = 30% DV• Milk
1 cup = 30% DV • Cheese
1 ½ oz. natural/2 oz. processed = 30% DV • Milk pudding
1/2 cup = 15% DV • Frozen yogurt, vanilla, soft serve
½ cup = 10% DV• Ice cream, vanilla
½ cup = 8% DV • Soy or rice milk, calcium-fortified
1 cup = varies—check label
Choose fat-free or low fat
most often
![Page 79: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/79.jpg)
% DV calcium: Grain products group
• Cereal, calcium- fortifiedServing size and amount of calcium varies—check label
![Page 80: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/80.jpg)
% DV calcium: Vegetable group
• Broccoli, raw1 cup = 9% DV
• Collards كرنب1/2 cup = 20% DV
• Turnip greens, لفت1/2 cup = 10% DV
![Page 81: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/81.jpg)
% DV calcium: Fruit group
• Orange juice and other calcium-fortified beverages6 oz. = 20 to 30% DV, varies—check label
Look for 100% juice
![Page 82: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/82.jpg)
% DV calcium: Meat & Beans Group
• Baked beans1 cup = 14% DV
• Salmon, canned, with edible bones3 oz. = 18% DV
• Sardines, canned, in oil, with edible bones3 oz. = 32% DV
• Soybeans, cooked1 cup = 26%
• Tofu, firm, with calcium ½ cup = 20% DV; check label
![Page 83: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/83.jpg)
Calcium supplement Calcium supplement considerationsconsiderations
![Page 84: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/84.jpg)
Calcium carbonate vs. citrate
Calcium carbonate• Needs acid to
dissolve and for absorption
• Less stomach acid as we age
• Often taken at meals when more stomach acid
Calcium citrate• Doesn’t require
stomach acid for absorption
• May be taken anytime—check with your healthcare provider
• May cost more
![Page 85: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/85.jpg)
Limit calcium to 500 mg at a time
Our bodies can best handle about 500 mg calcium at one time from food and/or supplements.
Spread your calcium sources throughout the day.
![Page 86: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/86.jpg)
Increase amount slowly• Start supplements with 500 mg
calcium daily for about a week, gradually adding more.
• Gas and constipation can be side effects:– Increase fluids and high fiber
foods if diet is low in whole grains and fruits and vegetables.
– Try a different type of supplement if side effects continue.
![Page 87: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/87.jpg)
87
Vitamin D from sunlight exposure• Vitamin D is manufactured in your skin
following direct exposure to sun.
• Amount varies with time of day, season, latitude and skin pigmentation.
• 10–15 minutes exposure of hands, arms and face 2–3 times/week may be sufficient (depending on skin sensitivity).
• Clothing, sunscreen, window glass and pollution reduce amount produced.
Source: National Osteoporosis Foundation Web site; retrieved July 2005 at http://www.nof.org
![Page 88: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/88.jpg)
You need more vitamin D as you age
Age
Daily vitamin D needs in International Units (IU)
![Page 89: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/89.jpg)
Food Sources of Vitamin DFood Sources of Vitamin D Cod liver oil – 1 TBS Salmon 3.5 oz. Mackerel 3.5 oz. Tuna, canned, in oil, 3 oz. Sardines 3.5 oz. Milk (fortified) 8 oz. Ready to eat cereal (fortified) ¾ -
1 cup Egg 1 whole Liver, 3.5 oz. Cheese, swiss 1 oz.
1,360 IU 360 345 200 250 98 40
20 15 12
![Page 90: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/90.jpg)
90
Sources of Vitamin D? Main dietary sources of vitamin D are:
• Fortified milk (400 IU per quart)
• Some fortified cereals
• Cold saltwater fish (Example: salmon, halibut, herring, tuna, oysters and shrimp)
• Some calcium and vitamin/mineral supplements
![Page 91: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/91.jpg)
Vitamin D PreparationsVitamin D Preparations
![Page 92: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/92.jpg)
![Page 93: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/93.jpg)
![Page 94: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/94.jpg)
FALL PREVENTION
![Page 95: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/95.jpg)
OsteoporosisFalls Break Bones
• You can prevent most falls– Improve your balance, coordination, and strength
through weight-bearing physical activity such as dancing or Tai Chi
– Review medicines with a health care professional (some medicines may cause drowsiness or dizziness)
– Have your vision checked– Make your home safer
![Page 96: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/96.jpg)
Protect Your BonesWays to Make Your Home Safer
1
2
3
4
5
6
7
8
9
10
11
Have handrails and plenty of light in all stairways.
Wear shoes that give good support and have non-slip soles.
Don’t use stepstools. Keep items you need within easy reach.
Maintain a clear path to the bathroom.
Make sure your walkways are wide enough.
Remove all small rugs. They can make you trip.
Move phone and electrical cords away from walkways and open areas.
Make sure that all areas are well lit. Use bright light bulbs.
Be aware that some medications, including over-the-counter medicines, can make you dizzy or sleepy.
Get your vision checked.
Remove things that you may trip over from stairs and places where you walk.
![Page 97: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/97.jpg)
Protect Your Bones Ways to Make Your Home Safer
12
5 Remove all small rugs. They can make you trip.
Use non-slip mats in the bathtub or shower. Have grab bars put in next to your toilet and in the bathtub or shower.
![Page 98: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/98.jpg)
![Page 99: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/99.jpg)
![Page 100: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/100.jpg)
Whom to Treat: NOF Guidelines 2014Whom to Treat: NOF Guidelines 2014Women ≥ 65 and men ≥ 70(younger with risk factors)
T-score between -1.0 and -2.5
T-score ≤ -2.5 in the lumbar spine, total hip, or femoral neck
or Hip or spine fracture (clinical or radiographic)
DXA test
≥ 3% for hip fracture or
≥ 20% for major osteoporotic fractures
FRAX10-y fracture risk
Candidate for TREATMENT
YES
YES
nof.org/hcp/resources/913. Accessed August 2014.
![Page 101: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/101.jpg)
Osteoporosis Therapy AlgorithmPostmenopausal Women
At Risk/Osteopenia Osteoporosis Severe OsteoporosisSTAGELowerHigher
-2.5BMD (T-score)
Raloxifene
PTH
CalcitoninHRTHRTHRTHRT
During Hot Flushes
Post Vasomotor SymptomsPre fracture Post Fracture
Risk of Fracture
AGE
Bisphosphonates Or Strontium Ranelate
50 55 60 65 70 75 80 85 90
![Page 102: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/102.jpg)
Osteoporosis Prevention and Treatment
Age
Hormonal Replacement
Bisphosphonates Strontium
SERM
20 40 60 80
Vitamin D
PTH
Life Style
Treatmentchoice
![Page 103: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/103.jpg)
One-Minute Treatment DecisionOne-Minute Treatment Decision
Therapy DecisionTreat all patients with an existing fracture
High Risk-Treat
Moderate Risk - Treat if other risk factors
Low Risk-Check again in 1-2 years
T-Score *
Below -2.0
-1.5 to -2.0
Above -1.5
National Osteoporosis Foundation, Physician’s Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica, Inc.; 1998.
![Page 104: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/104.jpg)
Osteoclast
Inhibition of resorption
Osteoblast
Stimulation of formation
Pharmacologic TreatmentTargets
![Page 105: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/105.jpg)
![Page 106: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/106.jpg)
Prevention Treatment
FDA-Approved Therapeutic Options
Estrogen
AlendronateRisedronateIbandronate
Zoledronic acidRaloxifene
Calcitonin
PTH (teriparatide)Denosumab
![Page 107: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/107.jpg)
![Page 108: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/108.jpg)
FDA-approved Medications
OsteoporosisPost-
menopausalGlucocorticoid-
induced Male
Drug Prevent Treat Prevent Treat
Estrogen
Calcitonin* (Miacalcin®, Fortical®)
Raloxifene (Evista®)
Ibandronate (Boniva®)
Alendronate (Fosamax®)
Risedronate (Actonel®)
Risedronate (Atelvia®)
Zoledronate (Reclast®)
Denosumab (Prolia™)
Teriparatide (Forteo®) Diab DL, Watts NB. Endocrinol Metab Clin North Am. 2013;42(2):305-317.
![Page 109: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/109.jpg)
DrugVertebra
l Fracture
Nonvertebral Fracture
Hip Fracture
Calcitonin Raloxifene Ibandronate Alendronate Risedronate Zoledronic acid Denosumab Teriparatide
Evidence for Fracture Reduction
Diab DL, Watts NB. Endocrinol Metab Clin North Am. 2013;42(2):305-317.
![Page 110: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/110.jpg)
![Page 111: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/111.jpg)
![Page 112: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/112.jpg)
Estrogen Treatment (ET)
• Several approved oral and transdermal preparations• Treats symptoms of estrogen deficiency• Skeletal effects:
– Decrease in biochemical markers of 50% to 60%– 2-year BMD increase of 4% to 6% at hip and spine– Decreased incidence of vertebral and hip fractures (34%) after 5
years in the Women’s Health Initiative (WHI)– Effects in women with osteoporosis have not been evaluated in
randomized controlled trials
• Concern about adverse effects• Long-term use not recommended
Rossouw JE, et al. Writing Group for the Women’s Health Initiative Investigators. JAMA. 2002;288:321-333.
![Page 113: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/113.jpg)
![Page 114: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/114.jpg)
The Concept of a SERMSelective Estrogen Receptor Modulator (EAAs: Estrogen Agonist/Antagonists)
Binds to the estrogen receptors
Produces an estrogen agonist effect in some tissues
Produces an estrogen antagonist effect in others
![Page 115: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/115.jpg)
Raloxifene• Raloxifene (60 mg daily)• Skeletal effects:
–Decrease in biochemical markers of 30%–3-year BMD increases of 2% to 3% at hip and spine–Decreased incidence of vertebral fractures (30% to 50%) in women with pre-existing vertebral fractures or low bone density. No effect on nonvertebral or hip fractures has been observed
• Extra-skeletal effects: reduction in invasive breast cancer
Ettinger B, et al. JAMA. 1999;282:637-645.
![Page 116: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/116.jpg)
Raloxifene Adverse effects
Hot flashes
2- to 3-fold increased risk of venous thromboembolic events
No increased risk of stroke, but Black Box Warning for increased risk of death following stroke
Leg cramps
Sontag A, Wan X, Krege JH. Curr Med Res Opin. 2010;26:71-76.
![Page 117: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/117.jpg)
Calcitonin
Calcitonin (200 units daily by nasal spray) Skeletal effects:
Decrease in biochemical markers of 20% Small effect (1% to 2%) on bone density in spine Reduced incidence of vertebral fractures (36%) in women with pre-
existing vertebral fractures No effect on nonvertebral or hip fractures has been observed
Adverse effects Nasal stuffiness Possible increased cancer risk
Chesnut CH 3d, et al. Am J Med. 2000;109:267-276. http://effectivehealthcare.ahrq.gov/slides/?pageaction=displaySlides&tk=49&dpg=9&scroll=314. Accessed: September 13, 2013. European Medicines Agency. Press release. July 20, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/07/WC500130122.pdf. Accessed: September 13, 2013.
![Page 118: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/118.jpg)
BisphosphonatesAlendronate, Risedronate, Ibandronate, and Zoledronic Acid
• Alendronate: 10 mg daily (tablet) or 70 mg weekly (tablet or liquid) for treatment, 5 mg daily or 35 mg weekly for prevention
• Risedronate: 5 mg daily or 35 mg weekly (tablet); 150 mg monthly (tablet)
• Ibandronate: 150 mg monthly by tablet; 3 mg intravenously over 15 to 30 seconds every 3 months
• Zoledronic acid: 5 mg by intravenous infusion over a minimum of 15 minutes once every year for treatment—and every other year for prevention
*2012 Jun 25;172(12):930-6
National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. Available at: http://www.nof.org/hcp/clinicians-guide. Accessed September 13, 2013.
![Page 119: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/119.jpg)
Clinical Benefit of Bisphosphonates• Relative risk reduction for fractures • Postmenopausal women with osteoporosis• 3 years bisphosphonate treatment
Vertebrae Hip
Khosla S, et al. J Clin Endocrinol Metab. 2012;97(7):2272-2282.
![Page 120: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/120.jpg)
![Page 121: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/121.jpg)
Bisphosphonates: Indications Treatment and prevention of postmenopausal
osteoporosis Alendronate, risedronate, ibandronate, zoledronic acid
Prevention and/or treatment of glucocorticoid-induced osteoporosis Risedronate, zoledronic acid, alendronate
Treatment of men with low bone density Alendronate, risedronate, zoledronic acid
![Page 122: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/122.jpg)
Contraindications/Warnings/Precautions– Hypocalcemia
– Creatinine clearance <30 cc/min (<35 cc/min for zoledronic acid)
– For oral dosing: Esophageal stricture or impaired esophageal motility (alendronate); inability to stand or sit for at least 30 minutes (alendronate/risedronate) or 60 minutes (ibandronate)
Notes: UGI symptoms per se are not a contraindication to oral dosing.Use in pregnancy: Class C
Oral dosing requirements– Tablets (with exception of delayed release risedronate) taken on an empty stomach
after overnight fast with 6 to 8 oz of plain water while in an upright position
– Patients should not eat or lie down for at least 30 minutes (alendronate and risedronate) or 60 minutes (ibandronate)
– Calcium and vitamin D supplements, if needed, should be taken at a different time of day than the oral bisphosphonate
Bisphosphonates
National Osteoporosis Foundation. Med Lett. 2011;53(1360):24.
![Page 123: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/123.jpg)
• “Class warning” regarding UGI symptoms (no increase in UGI complaints in randomized controlled trials)
• Influenza-like symptoms may occur after first monthly oral dose of IV bisphosphonate
• “Class warning” regarding infrequent bone, joint, and/or muscle pain
• “Class warning” regarding jaw osteonecrosis
• “Class warning” about atypical fractures following long-term therapy
Bisphosphonates: Side Effects
![Page 124: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/124.jpg)
“Osteonecrosis” of the Jaw (ONJ)
An area of exposed alveolar or palatal bone that typically shows poor healing over several months 95% of cases have been reported with high-dose,
chronic IV bisphosphonate treatment of myeloma and cancer metastatic to bone1
Can occur with denosumab2
Pain in 2/3 cases: infection may or may not be present Known risk factors: invasive dental procedures, oral
trauma, periodontitis, poor oral hygiene, radiotherapy to the jaw, chemotherapy, corticosteroids, infection
Pathogenesis is not known3
1. Woo SB, et al. Ann Intern Med. 2006;144:753-761. 2. Sutton EE, Riche DM. Ann Pharmacother. 2012;46:1000-1009.3. Khosla S, et al. J Bone Miner Res. 2007;22:1479-1491.
![Page 125: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/125.jpg)
Atypical Fractures of Femur in PatientsTaking Anti-Resorptive Agents Long Term
Park-Wyllie LY, et al. JAMA. 2011;305:783-789. Shane E, et al. J Bone Miner Res. 2013 May 28. [Epub ahead of print]. Watts NB, Diab DL. J Clin Endocrinol Metab. 2010;95:1555-1565. Meier RP. Arch Intern Med. 2012;172:930-936.
• May begin with stress reaction or stress fracture of lateral femoral cortex (A)
• Transverse fractures of femoral diaphysis or in subtrochanteric region (B)
• Often bilateral
• Prodromal pain in thigh or groin in 70%
• Occurs in untreated patients, but increased incidence with long-term antiresorptive therapy, particularly bisphosphonates and denosumab
![Page 126: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/126.jpg)
Bisphosphonate Therapy: “Long-Term” Treatment Stopping treatment in high-risk patients
After 5 years of alendronate-decline in BMD, rise in biochemical markers, no increased fracture risk except clinical vertebral fractures1
After 3 years of risedronate, spine BMD rose, vertebral facture risk was still reduced compared with control patients2
After 3 years of zoledronic acid, slight increase in morphometric fractures vs clinical vertebral fractures3
Long-term treatment has not clearly been associated with safety issues or loss of efficacy
Cessation of treatment after 2 to 5 years is associated with some persisting effect on biochemical markers, as well as BMD; this has been best characterized for alendronate and zoledronic acid
1. Black DM, et al. JAMA. 2006;296:2927-2938. 2. Watts NB, et al. Osteoporosis Int. 2008;19:365-372. 3. Black DM, et al. J Bone Miner Res. 2012;27:243-254.
![Page 127: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/127.jpg)
Recently Approved
• Boniva – 150 mg monthly– 2.5 mg daily approved May, 2003– Vertebral fracture efficacy shown with daily– Based on 1 year BMD data, 150 mg monthly is
superior to the 2.5 mg daily – 60 minute post dose fast, not 30 minute
• Fosamax PLUS D – 70 mg/2800 IU weekly
![Page 128: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/128.jpg)
How Long to Treat with bisphosphonates?
5–10 years appears to be safe for most patients Assess for risk:
Watts NB and Diab D. J Clin Endocrinol Metab. 2010;95(4):1555-1565.
Drug Holiday After 3-5 years
Drug Holiday After 10 years
Higher RiskLower Risk
![Page 129: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/129.jpg)
Baseline 3 Years
VERT-NA: Placebo Patient
Increased perforation
Trabecular thinning
Borah, et al, JBMR 16 (Suppl 1), 2001
![Page 130: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/130.jpg)
Similar thickness of trabeculae and number of perforations
Baseline 3 Years
Borah, et al, JBMR 16 (Suppl 1), 2001
VERT-NA: Risedronate Patient
![Page 131: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/131.jpg)
Bisphosphonates for Osteoporosis
• Benefit: reduction of fracture risk (alendronate, risedronate, ibandronate)
• Problem: poor adherence to therapy• Cause: multifactorial, including issues of
convenience (complexity of dosing) and tolerability (GI irritation in clinical experience)
• Possible solutions: larger doses given less frequently, parenteral administration
![Page 132: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/132.jpg)
Bisphosphonates: Molecular Mechanisms of Action
• Interfere with the action of osteoclasts– Recruitment, differentiation, and action– Two mechanisms:
• Incorporated into cytotoxic ATP analogs (etidronate)– Affect cellular activity
• Interfere with the mevalonate pathway (nitrogen-containing BPs)– Cause apoptosis
Russell R, et al. Osteoporos Int. 1999;(suppl 2):S68-S80.
![Page 133: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/133.jpg)
Bisphosphonates: Contraindications and Warnings
• Contraindications– Hypocalcemia– Known hypersensitivity to any component of this product– Inability to stand or sit upright for at least 30 minutes
• Warnings– Bisphosphonates may cause upper gastrointestinal disorders such as
dysphagia, esophagitis, and esophageal or gastric ulcer
.
![Page 134: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/134.jpg)
![Page 135: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/135.jpg)
![Page 136: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/136.jpg)
Denosumab Monoclonal antibody to RANKL 60 mg subcutaneous injection every 6 months 9% increase in spinal BMD after 3 years in the pivotal
FREEDOM trial; 4% to 5% increase in hip BMD Reduction in fracture risk after 3 years:
68% decrease in new vertebral fractures 40% decrease in hip fractures 20% decrease in nonvertebral fractures
8-year data: continued increase BMD, reduced bone turnover, good safety
Cummings SR, et al. N Engl J Med. 2009;368:756-765Prolia (prescribing information). Thousand Oaks, CA: Amgen; June 2012. McClung MR, et al. Osteoporos Int. 2013;24(1):227-235.
![Page 137: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/137.jpg)
Denosumab Binds RANK Ligand and Inhibits Osteoclast Formation, Function, and Survival
RANKL
RANK
OPG
Denosumab
Bone Formation Bone Resorption Inhibited
Osteoclast Formation, Function, and Survival Inhibited
CFU-GM PrefusionOsteoclast
Osteoblasts
HormonesGrowth Factors
Cytokines
Adapted from: Boyle WJ, et al. Nature. 2003;423:337-342.
![Page 138: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/138.jpg)
Proven osteoporotic fracture reductionthroughout the skeleton
In the pivotal FREEDOM study (published in the New England Journal of Medicine), Denosumab reduced the risk of fracture at key osteoporotic
fracture sites versus placebo
PROLIA®: PROTECTION AGAINST FRACTURE
The absolute risk reductions demonstrated for Prolia® versus placebo were 4.8%, 1.5% and 0.5% for vertebral, non-vertebral and hip fractures respectively. 1
6
P
![Page 139: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/139.jpg)
Denosumab Adverse EventsAdverse events that occurred more commonly in denosumab group (as listed in the PI):
Serious infections leading to hospitalization Dermatitis, eczema, rashes Back pain, pain in the extremity, musculoskeletal pain,
hypercholesterolemia, cystitis Pancreatitis Osteonecrosis of the jaw Significant suppression of bone remodeling
Prolia (prescribing information). Thousand Oaks, CA: Amgen; June 2012.
![Page 140: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/140.jpg)
Teriparatide: rhPTH [1-34]• The only treatment agent that is anabolic—stimulates bone
formation rather than inhibiting bone resorption• 20 μg daily (subcutaneously) for no more than 2 years• Indication: treatment of men and postmenopausal women
with osteoporosis who are at high risk for fracture • Effects:
– Increased bone density in spine by 9% and hip by 3% vs placebo over 18 months
– Reduced incidence of vertebral fractures (65%) and nonvertebral fragility fractures (53%) in women with pre-existing vertebral fractures
– Studies too small to evaluate effect on hip fractures• Adverse reactions: arthralgia, pain, nausea; warning about
osteosarcoma risk in ratsNeer RM, et al. N Engl J Med. 2001;344:1434-1441. Forteo (prescribing information). Indianapolis, IN: Eli Lilly and Company; March 21, 2012.
![Page 141: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/141.jpg)
![Page 142: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/142.jpg)
Latest in Osteoporosis Treatment1.Carotenoids, Lycopene Reduce Fracture Risk
(Antioxidants)
“…reactive oxygen intermediates may be involved in the bone-resorptive process and that fruit and vegetable-specific antioxidants, such as carotenoids, are capable of decreasing this oxidative stress. Therefore carotenoids may help in preventing osteoporosis.
In particular, an inverse relation of carotenoids and lycopene with biochemical markers of bone turnover has recently been demonstrated.”
J Bone Miner Res. 2009 Jun;24(6):1086-94.
![Page 143: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/143.jpg)
2.Omega-3 Fatty Acids Reduce hs-CRP1
“This study provides evidence that in healthy individuals, plasma n-3 fatty acid concentration is inversely related to hs-CRP…”
“High sensitivity C-reactive protein (hs-CRP) is a marker of low grade sustained inflammation.”
“Increased hs-CRP by just 1SD increases fracture risk by an amazing 23 percent2.”
Consider supplementing the diet with omega-3 fatty acids (fish oil). They’re a great way to help reduce inflammation, hs-CRP, cardiovascular disease, and fractures related to osteoporosis.
1. Micallef M A et al., European Journal of Clinical Nutrition, 2009; April 8 [Epub ahead of print].2. Pasco et al. JAMA. 2006;296(11):1353-1355
![Page 144: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/144.jpg)
3.Vitamin K Improves Bone Strength and Reduces FracturesReview of RCTs showed that vitamin K(1) and
vitamin K(2) supplementation reduced serum undercarboxylated osteocalcin levels regardless of dose but that it had inconsistent effects on serum total osteocalcin levels and no effect on bone resorption.”
Iwamoto J et al., Nutrition Research, 2009; 29(4): 221-228.
![Page 145: Shafei osteoporosis](https://reader035.vdocuments.net/reader035/viewer/2022062316/58ee42361a28abc0128b466b/html5/thumbnails/145.jpg)